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DIntroduction to the Single Ventricle Reconstruction trialEmile Bacha, MD,a and Pedro del Nido, MDbThe Single Ventricle Reconstruction (SVR) trial, sponsored
by the National Heart, Lung, and Blood Institute and carried
out by 15 clinical centers, randomized 549 neonates and
showed that transplantation-free survival at 14 months
was significantly higher overall with the right ventricle-
to-pulmonary artery shunt (RVPAS) compared with the
modified Blalock-Taussig shunt (MBTS).1 Any surgical
procedure that does not exceed 65% survival at 1 year de-
serves to be studied and scrutinized relentlessly. Although
the primary outcome was clear when considering the entire
study cohort, many questions remained regarding the
impact of comorbidities; intraoperative, postoperative, and
interstage management strategies on morbidity and mortal-
ity; and the mechanisms of death throughout the study
period.
The compilation of 5 follow-up articles2-6 represents
secondary analyses of the SVR trial, and their main value
is that they provide a more detailed analysis of areas that
could not be covered in the New England Journal of
Medicine article.1 The SVR trial fortunately included
enough study patients, and collected a vast amount of
data, to permit analysis of the interaction of risk factors
with shunt type2; the risk factors of hospital morbidity
and mortality after the Norwood3; the impact of shunt
type and other risk factors on interstage mortality4; the
cause, timing, and location of death after the Norwood5;
as well as a descriptive study on practice variation in perio-
perative care found across centers.6
Some of the findings confirm the findings of previous ret-
rospective studies or database extraction studies, such as the
impact of center/surgeon volume, the major and indepen-
dent role of extracardiac anomalies, genetic syndromes,
low gestational age and birth weight, smaller ascending
aorta, obstructed pulmonary venous return, and lower
socioeconomic status play on outcomes. Patients with aortic
stenosis/mitral stenosis did better than any other subgroup,
presumably because of the presence of antegrade aortic
flow, and patients with aortic atresia/mitral stenosis did
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880 The Journal of Thoracic and Cardiovascular Surgabsence of coronary fistulae was not documented. Another
novel and noteworthy finding of these secondary analyses
include the observation that term infants with aortic atresia
(51% of the cohort) did considerably better with an RVPAS
at 12 months (mortality one third that of a similar patient
with MBTS), which is significant and lines up neatly with
a physiologic explanation of superior diastolic coronary
flow and lack of coronary steal in RVPAS patients. Con-
versely, in 4% of the cohort (preterm infants with a patent
aortic valve), the MBTS was superior. No clear explanation
exists for this finding, and one could speculate that the ven-
triculotomy is less well tolerated in preterm infants. This
was a much smaller group of patients and thus statistical
inferences are more suspect. For term infants with a patent
aortic valve and for preterm infants with aortic atresia, no
clear difference between RVPAS and MBTS was seen.
This may be because the former group does well with either
shunt type and that, in the latter group, the benefit of the
RVPAS on coronary flow may be offset by the downsides
of a ventriculotomy.
Open sternum was identified as a significant risk factor
independent of the center’s strategy (elective vs routine ster-
nal closure). However, the study did show that, in selected
patients, primary sternal closure is a safe alternative. These
types of associations, however, are always difficult to inter-
pret because this ‘‘outcome variable’’ is dependent on the
surgeon’s decision at the end of the procedure and may
reflect patient instability or even a concern with technical
aspects of the surgery that are not captured by the usual
data-gathering process.
Other notable findings were that interstage mortality
was significantly better for the RVPAS compared with
MBTS, unless atrioventricular valve regurgitation was
moderate to severe, in which case this overshadowed the
shunt type and interstage mortality was similar. Not sur-
prisingly, most deaths occurred during initial hospitaliza-
tion. The nonspecific determination of ‘‘cardiovascular
death’’ was the most common cause, a sure way to frus-
trate readers who will long to get some clues as to what of-
ten remains an unexplained phenomenon: the sudden
unexplained death after Norwood. It is important to note
that whatever autopsy data were available were in large
part nonrevelatory.
In conclusion, these combined studies point to the
RVPAS as being beneficial in term infants with aortic
atresia and as being associated with lower interstage mortal-
ity in general. For term patients with aortic stenosis/mitral
stenosis, either shunt is associated with better survival.
These studies represent significant new knowledge. Sadly,
improved survival after Norwood, let alone quality of life,ery c October 2012
Bacha and del Nido Congenital Heart Diseaseremains an elusive goal that we as a profession are reaching
only incrementally.References
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